DRUG
Bright Minds Biosciences Inc

7,641
Mkt Cap
$546.01M
Volume
124,622.00
52W High
$70.23
52W Low
$23.18
PE Ratio
-57.84
DRUG Fundamentals
Price
$54.75
Prev Close
$54.47
Open
$54.41
50D MA
$52.93
Beta
0.98
Avg. Volume
104,646.00
EPS (Annual)
-$0.4777
P/B
10.21
Loading...
Loading...
News
all
press releases
Bright Minds Biosciences Inc. (DRUG) is on the Move, Here's Why the Trend Could be Sustainable
Bright Minds Biosciences Inc. (DRUG) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Zacks·17d ago
News Placeholder
More News
News Placeholder
Wall Street Analysts Believe Bright Minds Biosciences Inc. (DRUG) Could Rally 81.29%: Here's is How to Trade
The consensus price target hints at an 81.3% upside potential for Bright Minds Biosciences Inc. (DRUG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks·1mo ago
News Placeholder
Does Bright Minds Biosciences Inc. (DRUG) Have the Potential to Rally 114.07% as Wall Street Analysts Expect?
The consensus price target hints at an 114.1% upside potential for Bright Minds Biosciences Inc. (DRUG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks·2mo ago
News Placeholder
What's Going On With Bright Minds Biosciences Stock Friday?
Bright Minds Biosciences shares are moving higher on Friday. The company announced a $35 million non-brokered private placement. read more...
Benzinga·1y ago
News Placeholder
Bright Minds Biosciences Stock Back In Retail’s Spotlight With $35M Funding Round Via Private Placement
Just two days prior, Bright Minds announced promising data from preclinical testing of BMB-201, a non-opioid alternative for neuropathic pain relief
Stocktwits·1y ago
News Placeholder
Bright Minds Biosciences Stock Falls Pre-Market After Whopping 1,445% Gain, But Retail’s Still Hooked
The biotech company issued a press release late Tuesday stating it was “unaware of any material changes in the company’s operations that would account for the recent increase in market activity.”
Stocktwits·1y ago
News Placeholder
Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy
Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy Bright Minds Biosciences Initiates the...
PR Newswire·1y ago

Latest DRUG News

View

Advertisement|Remove ads.

Advertisement|Remove ads.